Scott Tagawa joins Alicia Morgans to discuss a randomized phase II study on a salvage anti-PSMA radioimmunotherapy targeting non-metastatic CRPC population. The study enrolled patients with high-risk non-metastatic CRPC, defined as a PSA doubling time of less than eight months or an absolute PSA of at least 20, low testosterone, and non-metastatic as defined by no evidence of metastasis on CT or MRI and bone scan. The primary endpoint was metastasis-free survival at 18 months. This study was performed in the pre-PSMA PET era, patients initially received a 4-week run-in with ketoconazole and hydrocortisone and then were randomized to receive either Lutetium or Indium, relabeled with J591, an antibody used to target PSMA. The high-level results of the study were that half of the patients developed metastatic disease at 18 months with Lutetium, whereas about 76% developed metastasis with Indium. The other secondary endpoints were all directionally in favor of Lutetium over Indium.

Biographies:

Scott Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, New York City, New York

Alicia Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts